Abstract
α-(-)-bisabolol is a natural monocyclic sesquiterpene present in the essential oil has generated considerable interest in the chemical and pharmaceutical industries and currently in use in various formulations, mainly in cosmetics. This study was undertaken to evaluate its therapeutic profile against skin inflammation using in-vitro, in-vivo and in-silico assays. Lipopolysachharide (LPS) and 12-O-tetradecanoyl-phorbol-13-acetate (TPA)-induced production of proinflammatory cytokines (TNF-α and IL-6) in macrophage cells as well as in TPA-induced skin inflammation in mice was significantly inhibited by α-(-)-bisabolol. TPA-induced ear thickness, ear weight and lipid peroxidation and histopathological damage in the ear tissue were also significantly inhibited by topical application of α-(-)-bisabolol in a dose dependent manner. In-vitro and in-vivo toxicity profiles indicate that it is safe for topical application on skin. Molecular docking study also revealed its strong binding affinity to the active site of the pro-inflammatory proteins. These findings suggested that α-(-)-bisabolol may be a useful therapeutic candidate for the treatment of skin inflammation.
Keywords: α-(-)-bisabolol, anti-inflammatory, macrophage, 12-O-tetradecanoylphorbol-13-acetate, mice, LPS.
Current Pharmaceutical Biotechnology
Title:α-(-)-bisabolol Reduces Pro-inflammatory Cytokine Production and Ameliorates Skin Inflammation
Volume: 15 Issue: 2
Author(s): Anil K. Maurya, Monika Singh, Vijaya Dubey, Suchita Srivastava, Suaib Luqman and Dnyaneshwar U. Bawankule
Affiliation:
Keywords: α-(-)-bisabolol, anti-inflammatory, macrophage, 12-O-tetradecanoylphorbol-13-acetate, mice, LPS.
Abstract: α-(-)-bisabolol is a natural monocyclic sesquiterpene present in the essential oil has generated considerable interest in the chemical and pharmaceutical industries and currently in use in various formulations, mainly in cosmetics. This study was undertaken to evaluate its therapeutic profile against skin inflammation using in-vitro, in-vivo and in-silico assays. Lipopolysachharide (LPS) and 12-O-tetradecanoyl-phorbol-13-acetate (TPA)-induced production of proinflammatory cytokines (TNF-α and IL-6) in macrophage cells as well as in TPA-induced skin inflammation in mice was significantly inhibited by α-(-)-bisabolol. TPA-induced ear thickness, ear weight and lipid peroxidation and histopathological damage in the ear tissue were also significantly inhibited by topical application of α-(-)-bisabolol in a dose dependent manner. In-vitro and in-vivo toxicity profiles indicate that it is safe for topical application on skin. Molecular docking study also revealed its strong binding affinity to the active site of the pro-inflammatory proteins. These findings suggested that α-(-)-bisabolol may be a useful therapeutic candidate for the treatment of skin inflammation.
Export Options
About this article
Cite this article as:
Maurya K. Anil, Singh Monika, Dubey Vijaya, Srivastava Suchita, Luqman Suaib and Bawankule U. Dnyaneshwar, α-(-)-bisabolol Reduces Pro-inflammatory Cytokine Production and Ameliorates Skin Inflammation, Current Pharmaceutical Biotechnology 2014; 15 (2) . https://dx.doi.org/10.2174/1389201015666140528152946
DOI https://dx.doi.org/10.2174/1389201015666140528152946 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chronic Paroxetine Treatment: Effects on Other Non-Serotonergic Neurotransmitter Systems
CNS & Neurological Disorders - Drug Targets Biological Variability and Targeted Delivery of Therapeutics for Inflammatory Bowel Diseases: An In Silico Approach
Inflammation & Allergy - Drug Targets (Discontinued) Chronic Tendon Pain: No Signs of Chemical Inflammation but High Concentrations of the Neurotransmitter Glutamate. Implications for Treatment?
Current Drug Targets Role of the Hsp90-Immunophilin Heterocomplex in Cancer Biology
Current Cancer Therapy Reviews Genetic and Environmental Modifiers of Alzheimers Disease Phenotypes in the Mouse
Current Alzheimer Research Glyco-Engineering of Human IgG-Fc to Modulate Biologic Activities
Current Pharmaceutical Biotechnology Endotoxin, Toll-like Receptor-4, and Atherosclerotic Heart Disease
Current Cardiology Reviews Editorial [Hot Topic: Designing New Drugs For High Grade Gliomas (Executive Guest Editor: Guido Frosina)]
Current Pharmaceutical Design Synthesis and Biological Evaluation of Bridged Analogues of the Platelet Aggregation Inhibitor Trifenagrel
Letters in Drug Design & Discovery Plant Polyphenols and Tumors: From Mechanisms to Therapies, Prevention, and Protection Against Toxicity of Anti-Cancer Treatments
Current Medicinal Chemistry Protein Kinase C Pharmacology: Perspectives on Therapeutic Potentials as Antidementic and Cognitive Agents
Recent Patents on CNS Drug Discovery (Discontinued) DNA Damage-inducing Compounds: Unraveling their Pleiotropic Effects Using High Throughput Sequencing
Current Medicinal Chemistry Probiotics and Gastrointestinal Disease: Clinical Evidence and Basic Science
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Attenuating Effect of Portulaca oleracea Extract on Chronic Constriction Injury Induced Neuropathic Pain in Rats: An Evidence of Anti-oxidative and Anti-inflammatory Effects
CNS & Neurological Disorders - Drug Targets Solid Lipid Nanoparticles Loaded with Fluorescent-labelled Cyclosporine A: Anti-Inflammatory Activity In Vitro
Protein & Peptide Letters Cerebral Hemorrhage Produced by Thrombolytic and Anti-Thrombotic Agents: A Review
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Bypass Mechanisms of Resistance to Tyrosine Kinase Inhibition in Chronic Myelogenous Leukaemia
Current Drug Discovery Technologies Human Galectin-3 Selective and High Affinity Inhibitors. Present State and Future Perspectives
Current Medicinal Chemistry Neuroprotective Effects of Tetracyclines: Molecular Targets, Animal Models and Human Disease
CNS & Neurological Disorders - Drug Targets Microglia:Neuroprotective and Neurotrophic Cells in the Central Nervous System
Current Drug Targets - Cardiovascular & Hematological Disorders